Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Overactive Bladder Age: Adult |
Dose: Tablet – 25 mg Frequency: once daily Duration: typically effective within 8 weeks Note: May increase to 50 mg by mouth once daily based on individual efficacy and tolerability |
|
Indication: Overactive Bladder Age: Adult Condition: Moderate Hepatic impairment (Child-Pugh B) |
Dose: Tablet – 25 mg Frequency: once daily Note: Not to exceed 25 mg/day |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Neurogenic detrusor overactivity Age: 3 years and older |
Dose: Oral – 24–48 mg Frequency: Once daily Note: Maximum Dose: 80 mg |
|
Indication: Neurogenic detrusor overactivity Age: 3 years and older |
Dose: Oral – 32–64 mg Frequency: Once daily Note: Maximum Dose: 80 mg |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Adult Condition: Renal impairment Severe (Creatinine Clearance 15-29 mL/minute) |
Dose: Tablet – Not to exceed 25 mg Frequency: once daily Note: Maximum dose 25 mg/day |
|
Age: Adult Condition: End Stage Renal Disease |
Dose: Tablet – Not recommended Note: Not recommended for use in End Stage Renal Disease |
Administration
- Can take with or without food
- Swallow whole
Side Effect
- Elevated BP occurring predominantly in patients with preexisting hypertension (7-11%)
- Dry mouth (3-9%)
- Nasopharyngitis (3-4%)
- UTI (3-6%)
- Headache (2-4%)
- Influenza (2-3%)
- Constipation (2-3%)
- Dizziness (2%)
- Arthralgia (2%)
- Cystitis (2%)
- Back pain (1-3%)
- Sinusitis (1-3%)
- URTI (1-2%)
- Arthralgia (1-2%)
- Diarrhea (1-2%)
- Tachycardia (1-2%)
- Fatigue (1%)
- Abdominal pain (0-1%)
- Reports of neoplasms (0-1%)
- palpitations
- elevated BP
- glaucoma, blurry vision
- dyspepsia, gastritis, abdominal distension
- Rhinitis
- Elevations in GGT, AST, ALT, LDH
- nephrolithiasis, bladder pain
- urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema
- Stevens-Johnson syndrome associated with increased serum ALT, AST and bilirubin
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Strong CYP3A/P-gp inhibitors (e.g. ketoconazole, itraconazole, ritonavir, clarithromycin)
|
Increased AUC
|
|
CYP3A/P-gp inducers
|
Decreased plasma concentration
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Severe Uncontrolled Hypertension
|
Risk of dangerous blood pressure rise
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store in a cool and dry place, protected from light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.